Niagen Bioscience gets license to develop, commercialize Niagen

Niagen Bioscience gets license to develop, commercialize Niagen

Niagen Bioscience, Inc. (NASDAQ: NAGE), a global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research, has secured an exclusive license to develop and commercialize its patented nicotinamide riboside (Niagen) molecule as a potential treatment for Parkinson’s disease (PD). The agreement, announced on July 8, 2025, is with Haukeland University Hospital, Bergen, Norway [1].

The collaboration, which builds on years of joint research and clinical trials, grants Niagen Bioscience exclusive rights to a robust body of scientific data and intellectual property. This includes findings from the NOPARK trial, the largest and most comprehensive clinical investigation of NAD+ augmentation in persons with early PD to date [2]. The trial, recently completed in June 2025, is expected to be published by the end of 2025.

Niagen Bioscience CEO, Rob Fried, stated, “This milestone underscores our long-term commitment to translating scientific innovation into meaningful therapeutic solutions. Through our partnership with Haukeland and its world-renowned researchers, we are taking bold steps into bringing NAD+-boosting therapies to address clinical unmet needs.”

Professor Charalampos Tzoulis, who leads the NOPARK study and the Neuro-SysMed center at Haukeland University Hospital, added, “This agreement represents a significant step in advancing knowledge and developing treatments that can truly benefit patients with PD and other neurodegenerative disorders.”

The license agreement also includes the formation of a wholly owned subsidiary, marking a pivotal step in Niagen Bioscience’s evolution from supplement science to regulated drug development. The company retains the right to either commercialize the drug candidate or sublicense the program to a strategic pharmaceutical partner to support regulatory advancement and commercialization.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors, and its team of world-renowned scientists collaborates with leading research institutions worldwide to uncover the full potential of NAD+.

References:
[1] https://www.stocktitan.net/news/LIMX/limitless-x-holdings-secures-100-000-strategic-funding-from-chairman-mh26cwf32i24.html
[2] https://www.businesswire.com/news/home/20250708472670/en/Niagen-Bioscience-Secures-Exclusive-License-to-Develop-and-Commercialize-its-NAD-Precursor-Patented-Nicotinamide-Riboside-Niagen-as-a-Potential-Parkinsons-Disease-Therapy-in-Agreement-with-Haukeland-University-Hospital-in-Bergen-Norway